MorphoSys AG ADR MORGAN Bond
MorphoSys AG ADR holds a debt-to-equity ratio of 2.315. . MorphoSys' financial risk is the risk to MorphoSys stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
MorphoSys' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. MorphoSys' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps MorphoSys Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect MorphoSys' stakeholders.
For most companies, including MorphoSys, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for MorphoSys AG ADR, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, MorphoSys' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
MorphoSys |
Popular Name | MorphoSys MORGAN STANLEY |
Equity ISIN Code | US6177602025 |
Bond Issue ISIN Code | US61772BAC72 |
MorphoSys AG ADR Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
MORGAN STANLEY | US61772BAC72 | Details | |
MPLX LP 4875 | US55336VAG59 | Details | |
MORGAN STANLEY | US61772BAB99 | Details | |
MPLX LP 4125 | US55336VAK61 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
MSTDLF 45 11 FEB 27 | US61774AAD54 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details | |
MGM Resorts International | US552953CD18 | Details | |
Valero Energy Partners | US91914JAA07 | Details |
Understaning MorphoSys Use of Financial Leverage
MorphoSys' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to MorphoSys' current equity. If creditors own a majority of MorphoSys' assets, the company is considered highly leveraged. Understanding the composition and structure of MorphoSys' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. The company was founded in 1992 and is headquartered in Planegg, Germany. Morphosys operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 648 people. Please read more on our technical analysis page.
Pair Trading with MorphoSys
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MorphoSys position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MorphoSys will appreciate offsetting losses from the drop in the long position's value.Moving against MorphoSys Stock
0.84 | MMV | MultiMetaVerse Holdings | PairCorr |
0.83 | THCPU | Thunder Bridge Capital | PairCorr |
0.7 | HSDT | Helius Medical Techn | PairCorr |
0.69 | OPTX | Syntec Optics Holdings Trending | PairCorr |
0.51 | CREVW | Carbon Revolution Public | PairCorr |
The ability to find closely correlated positions to MorphoSys could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MorphoSys when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MorphoSys - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MorphoSys AG ADR to buy it.
The correlation of MorphoSys is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MorphoSys moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MorphoSys AG ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MorphoSys can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in MorphoSys Stock
If you are still planning to invest in MorphoSys AG ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MorphoSys' history and understand the potential risks before investing.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.